| Accession |
PRJCA028074 |
| Title |
NOTCH1 mutation predicts better clinical survival benefit of tislelizumab in second-line esophageal squamous cell carcinoma: a RATIONALE-302 study biomarker analysis |
| Relevance |
Medical |
| Data types |
Exome
Raw sequence reads
|
| Organisms |
Mus musculus
|
| Description |
In a mouse model of esophageal cancer, we performed single-cell sequencing analysis on tumor tissues from mice with endogenous NOTCH1 knockout and control group mice. We found that NOTCH1 mutation promotes a more immunoactive tumor microenvironment. Retrospectively, we collected adjacent and tumor samples from 30 esophageal cancer patients for whole-exome sequencing. Additionally, we conducted multiplex immunofluorescence staining on patient tissue sections. Our study revealed that, compared to patients with wild-type NOTCH1, those with NOTCH1-mutated esophageal cancer exhibited significantly lower proportions of B cells and neutrophils in their tumor tissues. |
| Sample scope |
Multispecies |
| Release date |
2024-07-15 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Natural Science Foundation of China (NSFC)
|
|
92159106
|
|
| Science Foundation of Peking University Cancer Hospital
|
|
BJCH2024BJ01
|
|
| National Youth Top-Level Talent Support Program ("Ten Thousand Talents Scheme")
|
|
12Y4962
|
|
|
|
| Submitter |
Xi
Jiao (jiaoxi0102@163.com)
|
| Organization |
Peking University Cancer Hospital |
| Submission date |
2024-07-15 |
